pbi-1402

PBI-1402 is an orally active, low molecular weight synthetic compound developed for the treatment of anemia, particularly chemotherapy-induced anemia (CIA). It acts as an erythropoiesis-stimulating agent by promoting the proliferation and maturation of hematopoietic progenitor cells in both myeloid and erythroid cell populations. Unlike erythropoietin, PBI-1402 has a distinct mechanism of action that enhances red blood cell production and increases hemoglobin levels. Clinical studies have shown that it significantly raises hemoglobin and red blood cell counts in patients with CIA without significant side effects or need for transfusions. The drug is administered orally and has demonstrated good safety and tolerability profiles in clinical trials[1][4][5][6][8].